Chugai Pharmaceutical Co Ltd (4519)

34.5900 0.0000 (0.00%)
Close EUR Disclaimer

Chugai Pharmaceutical Co Ltd Company Profile

Equity Type
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Contact Information
Chuo,103-8324 Japan
81 3 3281 6611
81 3 3281 6607
Top Executives
Osamu Nagayama 75 1989 Honorary Chairman & Senior Advisor
Osamu Okuda 60 2014 President, CEO & Representative Director
Henry L. Nordhoff 81 0000 Chairman of the International Advisory Council
Sonosuke Kadonaga 71 0000 Member of the International Advisory Council
William A. M. Burns 76 0000 Member of the International Advisory Council
Andre S. Hoffmann 65 0000 Member of the International Advisory Council
Arnold J. Levine 83 0000 Member of the International Advisory Council
Christoph Franz 63 2017 Non-Executive Director
Fumio Tateishi 74 2023 Outside Independent Director
Hideo Teramoto 63 2023 Outside Independent Director
Mariko Y. Momoi 75 2020 Outside Independent Non-Executive Director
James H. Sabry 65 2019 Non-Executive Director
Kenichi Masuda 61 2020 Outside Independent Audit & Supervisory Board Member
Mami Yunoki 61 2024 Audit & Supervisory Board Member
Yumiko Waseda 64 2023 Outside Independent Audit & Supervisory Board Member
Hitoshi Itakura 54 0000 Director
Iwaaki Taniguchi 57 2022 Executive VP, Head of Finance Supervisory Division, CFO & Director
Yoshiaki Ohashi 64 2015 SVP & Full-time Audit Supervisory Board Member
Hitoshi Iikura 54 2024 VP, Head of Research Division & Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles